09/01/2026
🚨 Urgent Warning: Explosive Systematic Review Exposes Alarming Cancer Signals Following COVID-19 Vaccination
A newly published systematic review in Oncotarget (January 3, 2026) has compiled and analyzed 69 peer-reviewed studies and reports from 2020–2025, revealing consistent patterns of aggressive cancer behaviors in close temporal proximity to COVID-19 vaccination across 27 countries.
This first-of-its-kind global synthesis reveals replicated safety signals that regulators and health authorities continue to downplay at the public's peril.
📊 Key findings:
• Rapid progression, recurrence, or reactivation of cancers, often within weeks to months after vaccination
• Atypical presentations, including tumors at injection sites or regional lymph nodes
• 43% of reports focused on lymphoid malignancies (leukemias and lymphomas) with unusually aggressive courses
• 41% involved solid tumors such as breast, lung, melanoma, pancreatic, sarcomas, and others
Large-scale population evidence:
• South Korean nationwide cohort of 8.4 million individuals: Approximately 27% higher overall cancer risk post-vaccination, with elevated incidences of thyroid, colorectal, lung, breast, gastric, and prostate cancers
• Italian study of nearly 300,000 participants: Increased cancer-related hospitalizations among vaccinated groups, notably for bladder, breast, and colorectal cancers
• U.S. military longitudinal data: Sharp increases in certain lymphomas during 2021 amid widespread vaccine rollout
Renowned oncologist and review contributor Wafik El-Deiry, MD, PhD, described elements of these patterns as resembling a "smoking gun" for vaccine-associated risks, including hyperprogression and rapid-onset cancers.
He affirmed a real risk exists, with magnitude yet to be fully quantified.
Potential mechanisms highlighted:
• Spike protein interactions promoting tumor growth
• DNA contamination in vaccine batches activating oncogenes
• Severe immune dysregulation facilitating tumor escape and dormancy reactivation
These replicated patterns span dozens of independent studies, cancer types, and nations—demanding immediate accountability rather than continued evasion.
The authors call for comprehensive epidemiologic studies, clinical trials, histopathological examinations, forensic autopsies, and mechanistic research to uncover the full extent of these links.
Billions received novel gene-based platforms without prior carcinogenicity testing.
The ongoing refusal to confront these signals represents a profound betrayal of public trust.
How much evidence is required before action is taken?
đź”— Read the full review: https://www.oncotarget.com/article/28824/text/